Africa’s pharmaceutical market reached $27.65 billion in 2023 and is tracking toward $35 billion by 2032. South Africa alone is […]

The pharmaceutical R&D portfolio is the strategic core of the enterprise, a high-stakes arena where science, finance, and market dynamics

The patent system’s founding logic is straightforward: disclose an invention, receive a time-limited monopoly, then surrender it to the public.

Every blockbuster drug has two commercial lives. The first runs from approval to the loss of its composition-of-matter patent. The

The patent cliff bearing down on pharma between now and 2030 is not a scheduling problem. It is a structural

For pharma IP teams, portfolio managers, R&D leads, and institutional investors navigating the post-IRA, outcomes-contingent revenue landscape. The numbers are

A drug patent is not a legal document. It is a financial instrument — one whose value fluctuates from zero

The global biopharmaceutical deal machine ran at record velocity in 2024. China’s out-licensing deal value hit an estimated $47 billion,

Every year, pharmaceutical companies forfeit billions in recoverable IP value not because their science failed, but because their patent strategy